Ashkenazi Jews carry a handful of inherited gene changes that raise cancer risk far more often than in most populations, and the best known sit in the BRCA genes. About 1 in 40 Ashkenazi Jews carries one of them, roughly ten times the rate in most other groups.1PubMed Central. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry A carrier’s risk is raised, not settled, and most carriers can’t tell from their family tree that they have a change at all.
Why These Gene Changes Are Common in Ashkenazi Families
The Ashkenazi population shrank sharply at least twice, once around the start of the Diaspora and again between about 1100 and 1400.2PubMed Central. A Population-Genetic Test of Founder Effects and Implications for Ashkenazi Jewish Diseases It then grew very quickly from that small base.3PubMed. MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish population Gene changes that a few ancestors happened to carry became common by chance, not because they gave anyone an advantage.4PubMed Central. Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish population Doctors call these “founder mutations”: specific changes shared by many people descended from the same ancestors. Some are ancient. Two colon-cancer-related changes date to about the 600s.5PubMed Central. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome Finns and French Canadians, for example, have their own founder changes. Most Ashkenazi Jews carry none of the changes discussed here.
For testing, the useful part is that the same few changes keep recurring, so a cheap targeted test can check for them quickly. That is why Israel and some clinics offer a short “Jewish panel” rather than reading whole genes. It also means a carrier’s relatives are likely to share the identical change. Ashkenazi ancestry on only one side of the family still counts.
The Three BRCA Changes and What They Do to Risk
BRCA1 and BRCA2 are genes that help repair damaged DNA, and a harmful change in one weakens that repair. About 2% of Ashkenazi Jews carry one of three founder changes, two in BRCA1 and one in BRCA2.6PubMed Central. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families A home DNA test from 23andMe found one in about 1 in 46 people with mostly Ashkenazi ancestry.7PubMed Central. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry Rarer BRCA changes exist in Ashkenazi people too, so the three are the most common ones, not the only ones.
Cells pick up DNA damage constantly, and BRCA proteins help fix a particularly dangerous kind of break. A carrier is born with one working copy of the gene and one altered copy in every cell, so repair still works at first. Risk rises because a cell that later loses the working copy has no good way to fix its damage, and mistakes pile up.
Among carriers found in the general Ashkenazi community, lifetime breast cancer risk was about 36%, roughly three times average.8PubMed Central. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients For comparison, the general-population risk is about 1 in 8. Estimates from families already hit hard by cancer run much higher, around 70% by age 80.9PubMed Central. Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review Your own number depends partly on your family history, which a genetic counselor weighs.
Ovarian cancer is the bigger concern because it is hard to catch early. By age 70, risk is about 37% with a BRCA1 change and about 21% with a BRCA2 change, so BRCA1 carries the higher ovarian risk of the two.10Clinical Cancer Research. Ovarian Cancer Risk in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations Early symptoms are usually vague, like bloating, and no reliable screening test catches it early.
BRCA Risks for Men and Other Cancers
BRCA changes also raise the risk of male breast, pancreatic and prostate cancers and melanoma.11Basser Center. BRCA in the Jewish Population A man has the same 50% chance as a woman of passing a change to each child, so a father’s side of the family counts as much as a mother’s. A daughter’s risk can come entirely through her father.
A family where the gene runs through men can look free of risk even when it isn’t, and men are often never offered testing. A man whose mother or sister had breast cancer, or who himself had prostate or pancreatic cancer, has a real reason to ask. His result matters to his daughters and sons, his siblings and their children.
For male carriers, male breast cancer is rare, but a lump near the nipple deserves a check. Prostate cancer linked to BRCA2 can be more aggressive, so doctors may start PSA checks earlier.
Pancreatic cancer is uncommon but serious and usually found late. Its presence in a relative is a strong reason to raise testing with a doctor.
Colon and Uterine Cancer Risks
About 1 in 15 Ashkenazi Jews without cancer carries a change called APC I1307K.12PubMed Central. Ashkenazi Jewish and Other White APC I1307K Carriers Are at Higher Risk for Multiple Cancers It raises colon cancer risk about 1.5 to 1.75 times, and carriers tend to develop more polyps and get cancer somewhat younger.13PubMed Central. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism Yet it explains only about 3% to 4% of Ashkenazi colon cancer.14PubMed Central. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism
In practice, an I1307K result is not a reason for alarm or surgery. Most colon cancers grow slowly from polyps over years, which gives colonoscopy a window to catch and remove them, and removing polyps prevents most cancers from forming. A carrier with more polyps has more chances for that check to help, which is the reasoning behind more frequent colonoscopy, commonly starting around 40.
Lynch syndrome is an inherited condition that weakens a different DNA repair system and raises colon and uterine cancer risk. One Ashkenazi Lynch change, in the MSH2 gene, brings about a 61% risk of colon cancer by age 70 for men and women.15PubMed Central. High Risk of Colorectal and Endometrial Cancer in Ashkenazi families with the MSH2 A636P founder mutation Women with it face about a 56% risk of uterine cancer, often diagnosed in the early 50s.16PubMed Central. High Risk of Colorectal and Endometrial Cancer in Ashkenazi families with the MSH2 A636P founder mutation Two Ashkenazi changes in a related gene, MSH6, also raise colon and especially uterine cancer risk.17PubMed Central. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome Lynch syndrome also raises the risk of stomach and urinary tract cancers.
Care for Lynch syndrome is more intensive. Carriers usually get colonoscopy every one to two years starting in their 20s or 30s. Women may discuss removing the uterus and ovaries after finishing having children.
Lesser-Known Genes With Weaker or Uncertain Risks
An Ashkenazi CHEK2 change was found to roughly double breast cancer risk.18PubMed. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population A later look found it no more common in women with breast cancer, though it may be linked to pancreatic cancer.19PubMed. Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant A CHEK2 result is a reason to talk with a counselor, not to assume high risk.
Other genes matter little in this group. PALB2 and BRIP1 changes contribute only marginally to breast cancer in Jewish high-risk families.20PubMed. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families MUTYH changes, a cause of colon polyps in other groups, are rare in Ashkenazi Jews.21PubMed. Common MUTYH mutations and colorectal cancer risk in multiethnic populations
A result in CHEK2, PALB2 or BRIP1 usually leads to a plan shaped by family history, such as earlier or more frequent breast screening, not to surgery. The added risk is smaller and less certain than for BRCA genes, so counselors weigh the whole picture instead of one gene. Where evidence is unsettled, advice may change as more research appears.
Sometimes a report says “variant of uncertain significance.” That means the lab found a change it cannot yet classify. Most such variants are later found harmless, and doctors should not base surgery on one. Labs may reclassify it years later, so keep your contact details current with them.
Who Should Get Tested and Which Test to Choose
When Ashkenazi adults were tested regardless of family history, more than half the carriers found had no family history that would have flagged them.22PubMed Central. Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial Relying on family history alone catches fewer than half of carriers.23PubMed Central. Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial Many families are small, have few women, or lost relatives young to other causes, so the suspicious pattern never shows. Cancer passing through fathers is easy to miss, and some carriers simply never developed cancer. Testing only when the family tree looks alarming means carriers miss the chance to act early.
Testing all Ashkenazi women is cost-effective and prevents more cancers than testing by family history.24PubMed Central. Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing Researchers therefore recommend BRCA testing be available to all Ashkenazi Jewish women.25PubMed Central. Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies Israel offers it to Ashkenazi women free and without a referral.26PubMed Central. Privacy and utility of genetic testing in families with hereditary cancer syndromes living in three countries: the international cascade genetic screening experience
Home DNA tests look at only a sliver. Home tests like 23andMe check only the three founder BRCA changes.27PubMed Central. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry Among people having full clinical testing, harmful changes in cancer genes were about 17 times more common than the founder changes alone.28PubMed Central. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer A negative home result therefore does not rule out an inherited risk. It means none of the three changes were found, which is useful but narrow. With a personal cancer history or a strong family history, a negative result should not stop you from asking about full testing. A positive home result should be confirmed in a clinical lab before any major decision, because the home test is a screening tool.
To get a clinical test, ask a doctor or genetic counselor for a referral, or use a self-referral program where offered. A saliva or blood sample goes to a lab, and results take a few weeks. If you have a personal or family history, ask for a multigene panel, not only the three founder changes. In the US, a federal law bars health insurers and employers from using results, though not life insurers.
Jews from Iraq, Iran, Yemen, Morocco and other communities have their own founder BRCA changes, and a standard Ashkenazi panel can miss them. Mention mixed or non-Ashkenazi Jewish ancestry when ordering a test.
What Carriers Can Do to Lower Their Risk
Women carriers are usually advised to start breast screening younger and add MRI to mammograms.29National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet A common pattern is yearly MRI alternating with mammograms, so the breasts are checked at intervals through the year. MRI sees tumors that mammograms miss, especially in younger women with denser breast tissue. Starting ages differ by gene and guideline, so a high-risk clinic sets the exact schedule. Carriers with a close relative who had pancreatic cancer may be offered pancreas imaging.30National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet
Surgery offers the largest risk cut. Removing both breasts lowers breast cancer risk by about 90% to 95%.31PubMed. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review It has not been shown to help people live longer, likely because MRI screening catches cancers early. Both screening and mastectomy are accepted choices, not right or wrong. Screening keeps the breasts but means yearly MRI and possible callbacks. Mastectomy reduces worry for many but is major surgery with reconstruction choices.
Removing the ovaries and fallopian tubes cuts ovarian cancer risk by more than 96%.32PubMed Central. Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review It lowers breast cancer risk too, by about 72% with BRCA2 and 39% with BRCA1.33PubMed Central. Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review This surgery does improve survival.34PubMed. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review Unlike the breasts, the ovaries cannot be watched reliably, since no test has been shown to catch ovarian cancer early enough to save lives. That is why surgery is advised for ovarian risk while breast risk allows a choice between watching and operating.
Ovary removal is usually advised around 35 to 40 for BRCA1 and a bit later for BRCA2, after children. It causes immediate menopause, with hot flashes and bone and heart effects. Short-term hormone therapy is often considered safe for carriers without breast cancer. Some women first remove only the tubes and delay the ovaries.
Carriers who do get cancer have targeted options. Cancers in BRCA carriers can’t repair DNA well, so platinum chemotherapy and drugs called PARP inhibitors work especially well against them.35PubMed Central. The role of PARP inhibitors in BRCA mutated pancreatic cancer
What a Result Means for Your Relatives and Children
Each parent, sibling and child has a 50% chance of sharing your change. Testing relatives for a known family change, called cascade testing, is simple and cheap because the lab looks for one known change. Yet only about half of carriers’ adult relatives got tested, and men and more distant relatives were tested much less often.36Genetics in Medicine. Familial communication and cascade testing among relatives of BRCA population screening participants
Parents, siblings and adult children are the priority. Aunts, uncles and cousins have a smaller chance, but the change may well pass through their branch, so they should hear as well. Relatives on the side that carries the change are the ones who benefit, so there is usually no need to alarm the other side.
A copy of your lab report lets relatives’ doctors order the exact single test. A short letter from a genetic counselor can help with the conversation. Children are usually not tested until adulthood, since care starts in the 20s.
Fear, guilt about passing on a change, and worry about insurance or stigma can all keep relatives from testing. Framing the news as information that lets them act early, with a plan, often lands better than framing it as bad news. Relatives are free to decide on their own timing, and pressing them seldom helps.
Some carriers also weigh options for future children. Couples using IVF can test embryos for a known cancer gene change.37PubMed. Before the beginning: the genetic risk of a couple aiming to conceive Israeli carriers have both chosen and declined this, for personal reasons.38PubMed. Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers